MX2022001433A - Tratamiento personalizado de enfermedades oftalmologicas. - Google Patents

Tratamiento personalizado de enfermedades oftalmologicas.

Info

Publication number
MX2022001433A
MX2022001433A MX2022001433A MX2022001433A MX2022001433A MX 2022001433 A MX2022001433 A MX 2022001433A MX 2022001433 A MX2022001433 A MX 2022001433A MX 2022001433 A MX2022001433 A MX 2022001433A MX 2022001433 A MX2022001433 A MX 2022001433A
Authority
MX
Mexico
Prior art keywords
amd
personalized treatment
ophthalmologic diseases
macular edema
treatment
Prior art date
Application number
MX2022001433A
Other languages
English (en)
Inventor
Robert James Weikert
Aaron Osborne
Hugh Lin
David Andrew Silverman
Jeffrey R Willis
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2022001433A publication Critical patent/MX2022001433A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

La presente invención se refiere a anticuerpos que se unen a VEGF y ANG2 para su uso en el tratamiento de enfermedades vasculares oculares, tales como AMD neovascular (nAMD) (también conocida como neovascularización coroidea [CNV] secundaria a la degeneración macular relacionada con la edad [AMD] o AMD húmeda), retinopatía diabética, en particular, edema macular diabético (DME) o edema macular secundario a la oclusión de la vena retiniana (RVO).
MX2022001433A 2019-08-06 2020-08-06 Tratamiento personalizado de enfermedades oftalmologicas. MX2022001433A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962883499P 2019-08-06 2019-08-06
PCT/EP2020/072088 WO2021023804A1 (en) 2019-08-06 2020-08-06 Personalized treatment of ophthalmologic diseases

Publications (1)

Publication Number Publication Date
MX2022001433A true MX2022001433A (es) 2022-02-22

Family

ID=72193416

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001433A MX2022001433A (es) 2019-08-06 2020-08-06 Tratamiento personalizado de enfermedades oftalmologicas.

Country Status (11)

Country Link
US (1) US20220162296A1 (es)
EP (1) EP4010370A1 (es)
JP (2) JP7403553B2 (es)
KR (1) KR20220031666A (es)
CN (1) CN114341177A (es)
AU (1) AU2020326243A1 (es)
CA (1) CA3145239A1 (es)
IL (1) IL289405A (es)
MX (1) MX2022001433A (es)
TW (2) TWI785360B (es)
WO (1) WO2021023804A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023115046A1 (en) * 2021-12-17 2023-06-22 Genentech, Inc. Predicting optimal treatment regimen for neovascular age-related macular degeneration (namd) patients using machine learning
WO2023177691A1 (en) * 2022-03-15 2023-09-21 Regeneron Pharmaceuticals, Inc. Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
US20230295266A1 (en) * 2022-03-15 2023-09-21 Regeneron Pharmaceuticals, Inc. Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders
CN116738352B (zh) * 2023-08-14 2023-12-22 武汉大学人民医院（湖北省人民医院） 视网膜血管阻塞疾病的视杆细胞异常分类方法及装置

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
TWI426920B (zh) * 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
AU2012323849B2 (en) * 2011-10-13 2017-04-20 EyePoint Pharmaceuticals, Inc. Treatment of ocular disease
MY183712A (en) * 2012-07-13 2021-03-09 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
CA2904805A1 (en) * 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
SG11201508911PA (en) * 2013-04-29 2015-11-27 Hoffmann La Roche Human fcrn-binding modified antibodies and methods of use
CN108780663B (zh) * 2015-12-18 2022-12-13 科格诺亚公司 数字个性化医学平台和系统
BR112019019706A2 (pt) * 2017-03-22 2020-04-28 Genentech Inc conjugado de anticorpo, anticorpo, composição farmacêutica, métodos para reduzir ou inibir angiogênese e para tratar um distúrbio ocular
SG11202006712XA (en) * 2018-02-06 2020-08-28 Hoffmann La Roche Treatment of ophthalmologic diseases

Also Published As

Publication number Publication date
CN114341177A (zh) 2022-04-12
JP2022534351A (ja) 2022-07-29
IL289405A (en) 2022-02-01
JP7403553B2 (ja) 2023-12-22
KR20220031666A (ko) 2022-03-11
TW202120543A (zh) 2021-06-01
TWI785360B (zh) 2022-12-01
CA3145239A1 (en) 2021-02-11
US20220162296A1 (en) 2022-05-26
TW202317613A (zh) 2023-05-01
WO2021023804A1 (en) 2021-02-11
AU2020326243A1 (en) 2022-02-17
EP4010370A1 (en) 2022-06-15
JP2023123741A (ja) 2023-09-05

Similar Documents

Publication Publication Date Title
MX2022001433A (es) Tratamiento personalizado de enfermedades oftalmologicas.
AU2016204410A1 (en) Methods for treating vascular leak syndrome
MX2017016907A (es) Formulacion liquida estable de proteina de fusion con dominio fc de inmunoglobulina g (igg).
SG191334A1 (en) Use of a vegf antagonist to treat angiogenic eye disorders
MX2016009331A (es) Composiciones y metodos para tratar enfermedades oculares.
MX2014001019A (es) Dominios variables singulares anti-vgf fusionados con dominios de fc.
RU2014129316A (ru) Способы ингибирования глазного ангиогенеза
MX347226B (es) Tratamiento de enfermedad ocular.
MY176525A (en) Therapeutic agent for ocular disease or prophylactic agent for ocular disease
MX2020010968A (es) Formulaciones de bevacizumab tamponadas para usarse en el tratamiento de enfermedades.
WO2014031429A3 (en) Liposome formulations
WO2006039252A3 (en) Compositions and methods for treating ophthalmic diseases
WO2007075720A3 (en) Topical mecamylamine formulations for ocular administration and uses thereof
MX2018000869A (es) Metodos para tratar trastornos asociados con la angiogenesis y la neovascularizacion.
PH12020551015A1 (en) Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability
EA201992356A1 (ru) Способ и композиция для лечения заболевания, связанного с сетчаткой глаза, с использованием ингибитора ccr3
RU2017133101A (ru) Пептиды для ингибирования ангиогенеза
JP2018508528A5 (es)
WO2008152507A3 (en) Compositions and methods for treating ophthalmic disorders
MX2013001870A (es) Formulaciones oftalmicas de escualamina.
MX2019011242A (es) Farmacos y composiciones para el tratamiento de trastornos oculares.
ZA202204939B (en) Compounds for treatment of eye diseases associated with excessive vascularisation
Chia et al. The impact of switching anti-vascular endothelial growth factor therapy in the management of exudative age-related macular degeneration
Mayor et al. Ranibizumab for diabetic macular edema
CL2011001812A1 (es) Uso de deferiprona para prevenir yotratar un trastorno ocular relacionado con hierro seleccionado de : degeneracion macular relacionada con la edad, glaucoma, cataratas, retinopatía diabetica, degeneración hereditaria de la retina, desprendiimiento de la retina, retinopatía isquémica, entre otras.